anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ultrasound is a form of mechanical vibrational wave that can penetrate living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. Through actions such as cavitation, mechanical force vibration, and heat generation, ultrasound can induce a series of structural and functional changes in tissue cells, resulting in corresponding clinical effects.As early as 2006, research reported that ultrasound, when focused at specific depths beneath the nasal mucosa, creates scattered, punctate coagulation-type necrosis in the biological focus zone beneath the mucosa. This process involves the dissolution and disappearance of nuclei in some vascular smooth muscle cells, endothelial cell degeneration, partial thrombosis formation, vacuolar degeneration of neural cells, and partial or complete necrosis of glandular cells. The coagulation-type necrosis subsequently dissolves and is absorbed, while the structure of nasal mucosa cup cells, ciliated columnar epithelial cells, and basal cells remains normal, without damage to cilia and microvilli.Clinical studies indicate that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa. However, challenges exist in the current application of focused ultrasound for AR, including weak evidence from clinical studies, insufficient long-term efficacy observations, and limited understanding of treatment complications. Moreover, consensus is lacking on indications, treatment intensity, duration, safety, and complications avoidance, demanding urgent resolution.In light of these challenges and guided by the principle of "minimizing harm to patients in treatment," this study, centered on the minimally invasive surgical treatment of "reduction of hypertrophy" and "desensitization" in AR, aims to collaborate with six established tertiary hospitals in China proficient in ultrasound treatment for AR. The study will conduct a prospective multicenter clinical research to observe the clinical efficacy and safety of ultrasound focus in AR, explore its application value in AR, and promote the safe and effective clinical use of focused ultrasound in AR. The ultimate goal is to enhance the overall therapeutic effectiveness of AR, benefiting a large population of AR patients.
Participants will be administered one dose of a 25mg capsule of psilocybin. Two weeks later, the participant will be administered one more dose of a 25mg capsule of psilocybin.
PROBLEM TO BE SOLVED: To obtain an oral preparation of ibuprofen not having an unpleasant bitter taste. SOLUTION: This oral preparation of ibuprofen not substantially contains R(-)-2-(p-isobutylphenyl)propionic acid but contains S(+)-2-(p-isobutylphenyl) propionic acid expressed by the formula. Further, by suitably blending acid component (e.g.; citric acid), a sweetening agent, an aromatizing agent, a usually used medicinal excipient, etc., the mixture is prepared to a powder preparation, a granular preparation, a liquid preparation, a chewable tablet, a foaming preparation, a troche preparation, a rapidly disintegrating solid preparation, a chewing gum preparation, etc. The dose of ibuprofen eutomer is 5-10mg in the case of infant, >=1g, preferably 50-800mg for an adult as ibuprofen for one time dose to reduce a light pain. For the pain in the chronic case, 600-3200mg is administered daily by dividing it into one to several times.
The invention relates to a traditional Chinese medicine composition for treating qi-blood weakness type dysmenorrhea. The traditional Chinese medicine composition consists of the following components in parts by mass: 35-50 parts of Chinese angelica, 10-15 parts of codonopsis pilosula, 12-16 parts of rehmannia glutinosa, 9-12 parts of myrrh, 4-7 parts of rhizoma atractylodis macrocephalae, 3-5 parts of rhizoma corydalis, 6-9 parts of radix astragali, 12-15 parts of caulis spatholobi, 8-13 parts of amur silvergrass, 2-4 parts of aconitum kusnezoffii, 9-14 parts of phaseolus lunatus, 5-8 parts of fissistigma oldhamii, 6-10 parts of root of sandhill tylophora and 6-10 parts of radix chimonanthus. The traditional Chinese medicine composition is completely prepared from naturally pure traditional Chinese medicines and thus causes few side effects while the price is low. The tablets of the traditional Chinese medicine composition realize a remarkable curative effect on qi-blood weakness type dysmenorrhea. The cure rate of the tablets prepared from the traditional Chinese medicine composition on the qi-blood weakness type dysmenorrhea is up to 63.96%, and the obvious effective rate (including cure rate and effective rate) reaches 90.09%. The cure rate of the tablets prepared from the traditional Chinese medicine composition on the qi-blood weakness type dysmenorrhea is increased by 18.33%, and the obvious effective rate (including cure rate and effective rate) is increased by 11.11%.
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with NAPROSYN Suspension has any signs or symptoms of anemia, monitor hemoglobin or hematocrit. 

NSAIDs, including NAPROSYN Suspension, may increase the risk of bleeding events. Concomitant use of warfarin and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [see Drug Interactions (7)].
BACKGROUND: Assessment tools that assess pragmatic skills in adults with a mild-severe traumatic brain injury (TBI) are hard to access, not person-centred and have a high risk of clinician bias. The Pragmatics Profile is an informant report tool that was originally designed to assess pragmatic skills in people with a developmental disability.
AIMS: The aim of this study was to seek consensus from a panel of experts and create a version of the Pragmatics Profile for the TBI population.
METHODS AND PROCEDURES: A three-round modified Delphi methodology panel of 13 experts were invited to comment anonymously on the suitability of each question from the Pragmatics Profile modified for those with TBI until ≥ 80% agreement was reached.
OUTCOMES AND RESULTS: The Pragmatics Profile (TBI) included 66 questions that achieved consensus after three rounds of the Delphi panel. Qualitative analysis illuminated themes relating to adults with TBI and the need to include contextual factors.
CONCLUSIONS AND IMPLICATIONS: The outcome of this project was a revised version of the Pragmatics Profile which is suitable for adults with a mild-severe TBI, informed by experts and freely available online. Future research exploring the tool's utility and acceptability is the next step in its evaluation.
WHAT THIS PAPER ADDS: What is already known on this subject Assessment of the everyday functional use of language is challenging but vital. This is particularly true for those who have traumatic brain injury (TBI) where the communication outcomes can be highly variable and may include difficulties with conversational turn-taking, topic maintenance and reading social cues. There are limited tools available to clinicians and those tend to be rating scales or checklists which have a high risk of clinician bias. Available tools have a limited ability to capture the individual's personal social communication goals. What this paper adds to existing knowledge This study created an online Pragmatics Profile (PP) for TBI based on experts' opinions. This paper details the themes that emerged during the process of revising the PP for those with TBI. What are the potential or actual clinical implications of this work? The PP-TBI adds to the toolkit for speech and language therapists working with people with TBI. It meets recent recommendations in the literature to create an interview-based tool. The versatility of an online tool combined with revised input from a panel of experts increases the likelihood that clinicians will utilise this tool. Given the long-term use of the original PP by clinicians for almost 30 years and a focus on personalised care, the format and approach are also likely to be acceptable to clinicians.
The primary objective of this study is to characterize the safety, tolerability, and PK of GS-6624 after multiple IV administrations in patients with IPF. The secondary objectives are to evaluate the formation of anti-GS-6624 antibodies and to measure the effects of GS-6624 on FVC, DLCO, and SGRQ score. A total of 48 patients will be enrolled. In the double-blind phase (Part A), a total of 18 patients were enrolled at 3 dose levels. Part A was completed in October 2011.

In Part B, 30 patients will be enrolled at 2 dose levels. Part B is open-label and is currently enrolling.
PURPOSE:To produce a fat metabolism improving substance of a specific component consisting essentially of beta-glucan by removing protein from an extracted solution with an alkaline aqueous solution from grain, desalting and drying. CONSTITUTION:The whole grain flour or polished flour of preferably oat or barley is extracted with an alkali aqueous solution under heating. The residue is removed from the extracted solution, adjusted with an aqueous solution of an inorganic aid or organic acid to proper pH to precipitate protein. The protein is removed from the solution by centrifugal separation, etc., and the residue is concentrated. Then an alcohol is added to the concentrated solution and prepared precipitate is collected. The precipitate is washed preferably with ethanol several times, dried and ground to give a gum substance of grain effective for improving fat metabolism consisting essentially of beta-glucan. The concentrated solution is desalted by ultrafiltration having tens of thousands fractionated molecular weight, electrophoresis or ion exchange resin, dried and ground to produce the gum substance of grain.
A plant capsule formulation having high EPA content, comprising a functional formulation, and a capsule shell for wrapping the functional formulation. The functional formulation comprises at least 95% by mass of EPA and/or EPA alkyl esters. The capsule shell is a sealed structure and is not soluble in the functional formulation. The capsule shell is made from a first formula or a second formula. The first formula consists of a film-forming material, a humectant and water. In the first formula, the mass ratio of the film-forming material, the humectant and water is 1: 0.2-0.5: 1-1.4. The second formula consists of a hydroxypropyl starch, a plant gum, a plasticizer, and water. In the second formula, the mass percentage of the hydroxypropyl starch is 21% to 27%, the mass percentage of the plant gum is 11% to 13%, the mass percentage of the plasticizer is 19% to 29%, and the mass percentage of water is 35% to 45%. The capsule shell is a plant capsule shell, and the water content of the capsule shell is between 8% and 12%.
OBJECTIVE: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, with synovial fibroblasts (SFs) playing a pivotal role in its pathogenesis. Dysregulation of microRNA (miRNA) expression in SFs contributes to RA development. Exosomes (Exos) have emerged as effective carriers for therapeutic molecules, facilitating miRNA transfer between cells. This study explores the therapeutic potential of Exos derived from human umbilical cord mesenchymal stem cells (hUCMSCs), loaded with miR-451a, to modulate ATF2 expression, aiming to address RA in both in vivo and in vitro settings.
METHODS: In this study, hUCMSC and RA SFs were isolated and identified, and hUCMSC-Exos were extracted and characterized. The influence of hUCMSC-Exos on RA SFs was detected. And hUCMSC-Exos targeting RA SFs was traced. HUCMSCKD-AGO2 was prepared by knocking down AGO2 in hUCMSC. HUCMSCKD-AGO2-Exos was extracted and characterized,and their influence on RA SFs was detected. The miRNA profiles before and after hUCMSC-Exos intervention in RA SFs were mapped to identify differential miRNAs. RT-qPCR was used to verify the differential miRNAs, with hsa-miR-451a finally selected as the target gene. The effect of miR-451a on SFs was detected. The latent binding of miR-451a to activating transcription factor 2 (ATF2) was analyzed. The effect of hUCMSC-ExosmiR-451a on SFs was detected, and the expression of miR-451a and ATF2 was measured by RT-PCR. In vivo, hUCMSC-ExosmiR-451a was injected into the ankle joint of CIA rats, and arthritis index, joint imaging and synovial pathology were assessed. The expression of miR-451a and ATF2 in synovial tissue was detected. Finally, the safety of hUCMSC-ExosmiR-451a in CIA rats was evaluated.
RESULTS: This study revealed that hUCMSC-Exos can inhibit RA SFs proliferation, migration and invasion through miRNAs. High throughput sequencing detected 13 miRNAs that could be transmitted from hUCMSCs to RA SFs via hUCMSC-Exos. miR-451a inhibited RA SFs proliferation, migration and invasion by regulating ATF2. hUCMSC-Exos loaded with miR-451a targeted ATF2 to inhibit RA SFs proliferation, migration and invasion, and improve joint inflammation and imaging findings in CIA rats.
CONCLUSIONS: This study demonstrates that miR-451a carried by hUCMSC-Exos can play a role in inhibiting RA SFs biological traits and improving arthritis in CIA rats by inhibiting ATF2. The findings suggest a promising treatment for RA and provide insights into the mechanism of action of hUCMSC-Exos in RA. Future research directions will continue to explore the potential in this field.
Several lines of evidence suggest that schizophrenia is associated with accelerated aging and oxidative stress may play a role. Cognitive deficits are core symptoms of accelerated aging in patients with schizophrenia and the most difficult domain to treat. Current antipsychotics have limited, if any, efficacy for cognitive function. Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing not only clinical symptoms but also cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. This study aims to examine the efficacy and safety of NMDAE monotherapy for the treatment of schizophrenia. The investigators enroll patients with schizophrenia who refuse or are unable to tolerate antipsychotics due to poor response or adverse effects into a 6-week randomized, double-blind trial to receive monotherapy of NMDAE or placebo. The investigators biweekly measure clinical performances and side effects. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests. The efficacies of NMDAE and placebo will be compared.

Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.
PROBLEM TO BE SOLVED: To obtain a medicated cosmetic capable of activating the functions of skin without damaging the skin, promoting the regeneration of the skin and manifesting remarkable effects on improvement in common acne and skin roughening by formulating an extract solution from a leaf, etc., of Alpinia speciosa K. Schum. of the family Zingiberaceae with a cosmetic base. SOLUTION: This medicated cosmetic is obtained by formulating an extract solution or a pressed juice from a leaf or a stem of Alpinia speciosa K. Schum. of the family Zingiberaceae with a cosmetic base. The amount of the added extract solution or pressed juice from the Alpinia speciosa K. Schum. is 0.1-25 wt.% based on the cosmetic base. The cosmetic is capable of improving symptoms of common acne and skin roughening. The extract from the Alpinia speciosa K. Schum. is obtained by chopping the leaf or stem and extracting the chopped leaf or stem with water or a single organic solvent such as 1,3- butylene glycol and ethanol or a mixture thereof at normal temperatures or under heating.
Lenstar biometry will be performed on each eye prior to dilation. Subjects eyes will be dilated and subject will wait 20 minutes. Lenstar biometry will be performed after the 20 wait time.
In addressing the intricate challenges of enterocutaneous fistula (ECF) treatment, such as internal bleeding, effluent leakage, inflammation, and infection, our research is dedicated to introducing a regenerative adhesive hydrogel that can seal and expedite the healing process. A double syringe setup was utilized, with dopagelatin and platelet-rich plasma (PRP) in one syringe and Laponite and sodium periodate in another. The hydrogel begins to cross-link immediately after passing through a mixing tip and exhibits tissue adhesive properties. Results demonstrated that PRP deposits within the pores of the cross-linked hydrogel and releases sustainably, enhancing its regenerative capabilities. The addition of PRP further improved the mechanical properties and slowed down the degradation of the hydrogel. Furthermore, the hydrogel demonstrated cytocompatibility, hemostatic properties, and time-dependent macrophage M1 to M2 phase transition, suggesting the anti-inflammatory response of the material. In an in vitro bench test simulating high-pressure fistula conditions, the hydrogel effectively occluded pressures up to 300 mmHg. In conclusion, this innovative hydrogel holds promise for ECF treatment and diverse fistula cases, marking a significant advancement in its therapeutic approaches.
Both lysine and arginine methyltransferases are thought to be promising therapeutic targets for malignant tumors, yet how these methyltransferases function in malignant tumors, especially hepatocellular carcinoma (HCC), has not been fully elucidated. Here, we reported that SMYD4, a lysine methyltransferase, acts as an oncogene in HCC. SMYD4 was highly upregulated in HCC and promoted HCC cell proliferation and metastasis. Mechanistically, PRMT5, a well-known arginine methyltransferase, was identified as a SMYD4-binding protein. SMYD4 monomethylated PRMT5 and enhanced the interaction between PRMT5 and MEP50, thereby promoting the symmetrical dimethylation of H3R2 and H4R3 on the PRMT5 target gene promoter and subsequently activating DVL3 expression and inhibiting expression of E-cadherin, RBL2, and miR-29b-1-5p. Moreover, miR-29b-1-5p was found to inversely regulate SMYD4 expression in HCC cells, thus forming a positive feedback loop. Furthermore, we found that the oncogenic effect of SMYD4 could be effectively suppressed by PRMT5 inhibitor in vitro and in vivo. Clinically, high coexpression of SMYD4 and PRMT5 was associated with poor prognosis of HCC patients. In summary, our study provides a model of crosstalk between lysine and arginine methyltransferases in HCC and highlights the SMYD4-PRMT5 axis as a potential therapeutic target for the treatment of HCC.
OBJECTIVES: Several factors contribute to the anatomical complexity of the trochlear nerve, including small diameter, complex and longest intracranial course, deep location, and numerous neurovascular relationships. A 3-dimensional (3D) photorealistic model of the cranial nerves provides a detailed and immersive representation of the anatomy, enabling one to improve surgical planning, advanced surgical research, and training. The purpose of this work is to present a 3D photogrammetric study for a more intuitive and interactive way to explore and describe the entire course of trochlear nerve.
METHODS: Two injected-fixed head human specimens (4 sides) were examined. The dissection protocol was divided into the following steps: 1) brain hemisphere exposure; 2) hemispherectomy dissecting all cranial nerves and partial removal of the free edge of the tentorium; 3) middle fossa and lateral wall of cavernous sinus exposure; and 4) orbital exposure. A detailed 3D photogrammetric model was generated for each dissection step.
RESULTS: Four main volumetric models were generated during a step-by-step layered dissection of the entire nerve pathway highlighting its different segments. Finally, a full and integrated model of the entire course of the nerve was created. The models are available for visualization on monoscopic display, virtual, and augmented reality environment.
CONCLUSIONS: The present photogrammetric model provides a more comprehensive understanding of the nerve's anatomy in its different segments, allows for customizable views thus simulating different perspectives, and can be a valuable alternative to traditional dissections. It is an advanced tool for surgical planning and surgical simulation as well as virtual reality representation of the anatomy.
PURPOSE: To lower the intraocular pressure by using a 3-substituted-1- alkylamino-propanol deriv. having a β-adrenergic effect blocking characteristic. CONSTITUTION: The intraocular pressure is lowered particularly in glaucoma treatment by dosing a patient with the compd. of formula I X is O, CH2 , does not exist; Y is O, N-NH2 , N-NR1 R2 (R1 , R2 are H, a 1 to 8C alkyl; formula II to formula IV [R3 is R1 , COOR1 , CON(R1 )R2 ]; R is a 1 to 12C alkyl, a 7 to 20C aralkyl which may have methoxy on aryl; Ar is a 3-arom. residue or heterocyclic residue of 1-alkylamino-2-propanol having the β-adrenergic effect blocking characteristic having an arom. substituent or heterocyclic sunstitutent in a 3 position} or its pharmacologically permissible acid addition salt in the amt. effective for lowering the eye drop. This compd. is the precursor of the β-adrenergic effect blocking agent and is converted to the compd. of formula V via the corresponding ketone intermediate of the formula I in which Y is O in the visual tissues, by which the β-adrenergic effect blocking characteristic is exhibited.
Systems and methods for targeted area recommendation and guidance during radiation ablation treatment planning are disclosed. In some examples, a computing device receives (702) image data from one or more modes for a patient. The computing device determines (708) a recommended targeting region for the treatment based on the image data, and determines one or more corresponding segments of the segment model based on the recommended targeting region. Further, the computing device displays a segment model identifying the determined one or more segments and receives (710) input data modifying the determined one or more segments. Based on the input data, the computing device updates (716) the one or more segments and generates targeting definition data characterizing the updated one or more segments. The computing device transmits targeting definition data for treating the patient.